Cortactin expression in a Norwegian cohort of human papilloma virus negative oral squamous cell carcinomas of the mobile tongue.
invasion
organotypic culture
tumor budding
Journal
European journal of oral sciences
ISSN: 1600-0722
Titre abrégé: Eur J Oral Sci
Pays: England
ID NLM: 9504563
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
20
07
2022
accepted:
26
01
2023
pubmed:
16
2
2023
medline:
17
3
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Oral squamous cell carcinoma of the tongue (OTSCC) is the most common malignancy among oral squamous cell carcinomas and is frequently associated with an unfavorable prognosis. Local spread and distant metastasis are important causes of poor prognosis in OTSCC. Cortactin amplification and overexpression, a common molecular alteration in oral squamous cell carcinomas, have been linked to invasion and metastasis of tumor cells. However, the intra-tumor expression pattern and prognostic significance of cortactin in human papillomavirus (HPV) negative OTSCC is not fully investigated. Immunohistochemical analysis using tissue microarray consisting of formalin-fixed and paraffin-embedded HPV negative OTSCC (n = 123) specimens showed overexpression of cortactin at tissue cores from invading fronts as compared to the corresponding center cores. High overall cortactin expression was found to be associated with advanced (larger) tumor size and the occurrence of distance metastasis. Kaplan-Meier survival analysis showed that patients with high overall cortactin expression were associated with reduced 5-year survival. Multivariate Cox regression analysis identified high cortactin expression to be an independent prognostic factor in OTSCC. Additionally, siRNA-mediated silencing of cortactin was found to suppress the proliferative and invasive abilities of OTSCC cells in an organotypic co-culture model. Overexpression of cortactin is a promising prognostic marker in HPV-negative OTSCC.
Substances chimiques
Cortactin
0
CTTN protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12925Informations de copyright
© 2023 Scandinavian Division of the International Association for Dental Research. Published by John Wiley & Sons Ltd.
Références
Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am. 2015;24:491-508.
Ng JH, Iyer NG, Tan MH, Edgren G. Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck. 2017;39:297-304.
Kang CJ, Lin CY, Wang HM, Fan KH, Ng SH, Lee LY, et al. The number of pathologically positive lymph nodes and pathological tumor depth predicts prognosis in patients with poorly differentiated squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys. 2011;81:e223-30.
Tirelli G, Gatto A, Boscolo Nata F, Bussani R, Piccinato A, Marcuzzo AV, et al. Prognosis of oral cancer: a comparison of the staging systems given in the 7th and 8th editions of the American Joint Committee on Cancer Staging Manual. Br J Oral Maxillofac Surg. 2018;56:8-13.
Zanoni DK, Patel SG, Shah JP Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep. 2019;21:52. https://doi.org/10.1007/s11912-019-0799-x
Elseragy A, Salo T, Coletta RD, Kowalski LP, Haglund C, Nieminen P, et al. A proposal to revise the histopathologic grading system of early oral tongue cancer incorporating tumor budding. Am J Surg Pathol. 2019;43:703-9.
Wong T, Wiesenfeld D Oral cancer. Aust Dent J. 2018;63 (Suppl 1):S91-S9.
Soland TM, Bjerkli IH, Georgsen JB, Schreurs O, Jebsen P, Laurvik H, et al. High-risk human papilloma virus was not detected in a Norwegian cohort of oral squamous cell carcinoma of the mobile tongue. Clin Exp Dent Res. 2021;7:70-7.
Mooren JJ, Gultekin SE, Straetmans JM, Haesevoets A, Peutz-Kootstra CJ, Huebbers CU, et al. P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias. Int J Cancer. 2014;134:2108-17.
Gultekin SE, Senguven B, Klussmann JP, Dienes HP P16(INK 4a) and Ki-67 expression in human papilloma virus-related head and neck mucosal lesions. Invest Clinica. 2015;56:47-59.
Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35:747-55.
Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576-82.
Ramos-Garcia P, Gonzalez-Moles MA, Ayen A, Gonzalez-Ruiz L, Ruiz-Avila I, Gil-Montoya JA Prognostic and clinicopathological significance of CTTN/cortactin alterations in head and neck squamous cell carcinoma: Systematic review and meta-analysis. Head Neck. 2019;41:1963-78.
Ramos-Garcia P, Ruiz-Avila I, Gil-Montoya JA, Ayen A, Gonzalez-Ruiz L, Navarro-Trivino FJ, et al. Relevance of chromosomal band 11q13 in oral carcinogenesis: An update of current knowledge. Oral Oncol. 2017;72:7-16.
Yamada S, Yanamoto S, Kawasaki G, Mizuno A, Nemoto TK Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma. Pathol Oncol Res. 2010;16:523-31.
Horn D, Gross M, Dyckhoff G, Fuchs J, Grabe N, Weichert W, et al. Cortactin expression: association with disease progression and survival in oral squamous cell carcinoma. Head Neck. 2018;40:2685-94.
de Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernandez P, Allonca E, Garcia-Pedrero JM. Cortactin and focal adhesion kinase as predictors of cancer risk in patients with premalignant oral epithelial lesions. Oral Oncol. 2012;48:641-6.
Kelley LC, Weed SA Cortactin is a substrate of activated Cdc42-associated kinase 1 (ACK1) during ligand-induced epidermal growth factor receptor downregulation. PLoS One. 2012;7:e44363. https://doi.org/10.1371/journal.pone.0044363
van Kempen PM, Noorlag R, Braunius WW, Moelans CB, Rifi W, Savola S, et al. Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2015;4:1525-35.
Bjerkli IH, Jetlund O, Karevold G, Karlsdottir A, Jaatun E, Uhlin-Hansen L, et al. Characteristics and prognosis of primary treatment-naive oral cavity squamous cell carcinoma in Norway, a descriptive retrospective study. PLoS One. 2020;15:e0227738. https://doi.org/10.1371/journal.pone.0227738
Wittekind CKM, Greene FL, Hutter RVP, Sobin LH. TNM Atlas 2005: Illustrated guide to the TNM/pTNM classification of malignant tumours. 5th ed. Berlin Germany: Springer-Verlag Berlin and Heidelberg; 2005. p. 5-38.
Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29:167-78.
Gao J, Li X, Li D, Liu Y, Cao W, Chen X, et al. Quantitative immunohistochemistry (IHC) analysis of biomarker combinations for human esophageal squamous cell carcinoma. Ann Transl Med. 2021;9:1086. https://doi.org/10.21037/atm-21-2950
Kim SW, Roh J, Park CS Immunohistochemistry for pathologists: protocols, pitfalls, and tips. J Pathol Transl Med. 2016;50:411-8.
Pandey S, Soland TM, Bjerkli IH, Sand LP, Petersen FC, Costea DE, et al. Combined loss of expression of involucrin and cytokeratin 13 is associated with poor prognosis in squamous cell carcinoma of mobile tongue. Head Neck. 2021; 43: 3374-85.
Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ, et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer. 2001;92:869-74.
Rheinwald JG, Beckett MA Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res. 1981;41:1657-63.
Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med. 2007;36:594-603.
Fleming JC, Woo J, Moutasim K, Mellone M, Frampton SJ, Mead A, et al. HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. Br J Cancer. 2019;120:356-67.
Schreurs O, Balta MG, Karatsaidis A, Schenck K Composition of hemidesmosomes in basal keratinocytes of normal buccal mucosa and oral lichen planus. Eur J Oral Sci. 2020;128(5):369-78.
Almangush A, Coletta RD, Bello IO, Bitu C, Keski-Santti H, Makinen LK, et al. A simple novel prognostic model for early stage oral tongue cancer. Int J Oral Maxillofac Surg. 2015;44:143-50.
Ranftl RE, Calvo F Analysis of breast cancer cell invasion using an organotypic culture system. Methods Mol Biol. 2017;1612:199-212.
Makitie AA, Almangush A, Rodrigo JP, Ferlito A, Leivo I Hallmarks of cancer: tumor budding as a sign of invasion and metastasis in head and neck cancer. Head Neck. 2019;41:3712-8.
Yamada S, Yanamoto S, Rokutanda S, Miyakoshi M, Naruse T, Kawakita A, et al. Co-overexpression of cortactin and CRKII increases migration and invasive potential in oral squamous cell carcinoma. J Oral Max Surg Med. 2014;26:14-21.
Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, et al. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer. 2008;98:956-64.
Liu YC, Ho HC, Lee MR, Yeh CM, Tseng HC, Lin YC, et al. Cortactin is a prognostic marker for oral squamous cell carcinoma and its overexpression is involved in oral carcinogenesis. Environ Toxicol. 2017;32:799-812.
Ramos-Garcia P, Gonzalez-Moles MA, Gonzalez-Ruiz L, Ayen A, Ruiz-Avila I, Navarro-Trivino FJ, et al. An update of knowledge on cortactin as a metastatic driver and potential therapeutic target in oral squamous cell carcinoma. Oral Dis. 2019;25:949-71.
Boeve K, Mastik MF, Slagter-Menkema L, van Dijk BAC, Roodenburg JLN, van der Laan B, et al. Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm. Head Neck. 2021;43:2688-97.
Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ, Weaver AM Cortactin promotes cell motility by enhancing lamellipodial persistence. Current Biol. 2005;15:1276-85.
Croucher DR, Rickwood D, Tactacan CM, Musgrove EA, Daly RJ Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells. Mol Cell Biol. 2010;30:5057-70.
Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res. 2007;67:9304-14.
Squier CA, Kremer MJ Biology of oral mucosa and esophagus. J Nat Cancer Institute Monographs. 2001;29:7-15.
Mitre GP, Balbinot KM, Ribeiro ALR, da Silva Kataoka MS, de Melo Alves Junior S, de Jesus Viana Pinheiro J. Key proteins of invadopodia are overexpressed in oral squamous cell carcinoma suggesting an important role of MT1-MMP in the tumoral progression. Diagn Pathol. 2021;16:33. https://doi.org/10.1186/s13000-021-01090-7
Chang H, Chen D, Ni B, Zuo Q, Wang C, Han R, et al. Cortactin mediates apoptosis of gastric epithelial cells induced by VacA protein of Helicobacter pylori. Dig Dis Sci. 2016;61:80-90.
Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-9.
Dhir R Tissue microarrays: an overview. Methods Mol Biol. 2008;441:91-103.
Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N, et al. A new approach to the validation of tissue microarrays. J Pathol. 2006;208:607-14.